Pyrazolopyrimidine compounds as jak inhibitors
A compound, C1-C6 technology, used in organic chemistry, drug combinations, medical preparations containing active ingredients, etc., can solve problems such as defective signal transduction
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example
[0258] General Experimental Details
[0259] All solvents and commercially available reagents were used as received unless otherwise stated. In the case of product purification by silica gel chromatography, a glass column manually packed with silica gel (Kieselgel 60, 220-440 mesh, 35-75 μm) was used or A SPE Si II column was used for this operation. "Isolute SPE Si column" refers to the column containing 50μμm average particle size and nominal Prepacked polypropylene column of unbonded reactive silica with irregular particles of porosity. currently using In the case of the SCX-2 column, " "SCX-2 column" refers to a prepacked polypropylene column containing an unblocked propylsulfonic acid functionalized silica strong cation exchange sorbent.
[0260] LCMS conditions
[0261] Method A (LCMS15)
[0262] The experiment was carried out on SHIMADZU 20A HPLC, using C18 reverse phase column (50x 3mm Shim-Pack XR-ODS, 2.2μm particle size), the eluent was: solvent A: water ...
example 2
[0411] Example 2: First fraction, RT 1 =19.63min; 41.9mg white solid (S)-N-[3-[5-chloro-2-(difluoromethoxy)phenyl)-1-(1-methyl-2-oxopyrrolidine- 3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; LC / MS (Method F, ESI): [M+H] + =502.2,R T =1.63min, 1 H NMR (400MHz, DMSO-d 6 ): δ(ppm)9.76(s,1H),9.36(dd,J=6.8,1.6Hz,1H),8.70–8.69(m,2H),8.43(s,1H),7.65(dd,J=8.8 ,2.4Hz,1H),7.59(d,J=2.4Hz,1H),7.46(d,J=8.8Hz,1H),7.31(dd,J=7.2,4.4Hz,1H),7.27(t,J =73.2Hz, 1H), 5.29–5.25(m, 1H), 3.54–3.51(m, 1H), 3.45–3.42(m, 1H), 2.83(s, 3H), 2.60–2.55(m, 2H).
example 3
[0412] Example 3: Second fraction, RT2 = 24.74min; 40.1 mg white solid (R)-N-[3-[5-chloro-2-(difluoromethoxy)phenyl)-1-(1-methan yl-2-oxopyrrolidin-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; LC / MS (Method F, ESI): [M+H] + =502.2,R T = 1.61min, 1 H NMR (300MHz, DMSO-d 6 ): δ(ppm)9.76(s,1H),9.36(dd,J=6.8,1.6Hz,1H),8.70–8.69(m,2H),8.43(s,1H),7.65(dd,J=8.8 ,2.4Hz,1H),7.59(d,J=2.4Hz,1H),7.46(d,J=8.8Hz,1H),7.31(dd,J=7.2,4.4Hz,1H),7.27(t,J =73.2Hz, 1H), 5.29–5.25(m, 1H), 3.54–3.51(m, 1H), 3.45–3.42(m, 1H), 2.83(s, 3H), 2.60–2.55(m, 2H).
[0413] General Method 3: Examples 4 and 5
[0414]
[0415] N-(3-(5-chloro-2-(difluoromethoxy)phenyl)-1-(2-oxopyrrolidin-3-yl)-1H-pyrazol-4-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamide (isomer 1) and
[0416] N-(3-(5-chloro-2-(difluoromethoxy)phenyl)-1-(2-oxopyrrolidin-3-yl)-1H-pyrazol-4-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamide (isomer 2)
[0417] To a solution of Intermediate A (100 mg, 0.247 mmol) in DMF (10 mL) ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com